The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial
Open accessAbstract
Emerging data show that increased serum uric acid (SUA) concentration is an independent risk factor for end-stage renal disease. Treatment with the antihypertensive drug losartan lowers SUA. Whether reductions in SUA during losartan therapy are associated with renoprotection is unclear. We therefore tested this hypothesis. In a post hoc analysis of 1342 patients with type 2 diabetes mellitus and nephropathy participating in the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial, we determined the relationship between month 6 change in SUA and renal endpoints, defined as a doubling of serum creatinine or end-stage renal disease. Baseline SUA was 6.7 mg/dL in placebo and losartan-treated subjects. During the first 6 months, losartan lowered SUA by −0.16 mg/dL (95% CI: −0.30 to −0.01; P =0.031) as compared with placebo. The risk of renal events was decreased by 6% (95% CI: 10% to 3%) per 0.5-mg/dL decrement in SUA during the first 6 months. This effect was independent of other risk markers, including estimate glomerular filtration rate and albuminuria. Adjustment of the overall treatment effects for SUA attenuated losartan's renoprotective effect from 22% (95% CI: 6% to 35%) to 17% (95% CI: 1% to 31%), suggesting that approximately one fifth of losartan's renoprotective effect could be attributed to its effect on SUA. Losartan lowers SUA levels compared with placebo treatment in patients with type 2 diabetes mellitus and nephropathy. The degree of reduction in SUA is subsequently associated with the degree in long-term renal risk reduction and explains part of losartan's renoprotective effect. These findings support the view that SUA may be a modifiable risk factor for renal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Yu, M.-A., Sánchez-Lozada, L. G., Johnson, R. J., & Kang, D.-H. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328337da1d · Cited by 626
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371
Cited by
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
Zoppini, G., Targher, G., Chonchol, M., Ortalda, V., Abaterusso, C., Pichiri, I., Negri, C., & Bonora, E. (2012) · Diabetes Care · doi:10.2337/dc11-1346 · Cited by 274
Insights into predicting diabetic nephropathy using urinary biomarkers
Khan, N. U., Lin, J., Liu, X., Li, H., Lu, W., Zhong, Z., Zhang, H., Waqas, M., & Shen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140475 · Cited by 90
Metadata
- Authors
- Miao, Y., Ottenbros, S. A., Laverman, G. D., Brenner, B. M., Cooper, M. E., Parving, H.-H., Grobbee, D. E., Shahinfar, S., de Zeeuw, D., & Lambers Heerspink, H. J.
- Venue
- Hypertension
- Published
- 2011-07
- Volume
- 58
- Issue
- 1
- Pages
- 2-7
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2113961225
- Cited by
- 182
- References
- 3
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial. https://app.cochat.ai/papers/10.1161/hypertensionaha.111.171488
- The paper
- Miao, Y., Ottenbros, S. A., Laverman, G. D., Brenner, B. M., Cooper, M. E., Parving, H.-H., Grobbee, D. E., Shahinfar, S., de Zeeuw, D., & Lambers Heerspink, H. J. (2011). Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial. Hypertension. https://doi.org/10.1161/hypertensionaha.111.171488
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.